Fig. 2From: PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 studyPercentage change in LDL-C during treatment. Mean percentage changes (standard error) in LDL-C from baseline to end of treatment (i.e., at week 16 for patients receiving treatment Q4W and Q8W and at week 24 for patients receiving treatment Q12W) are shown. LDL-C low-density lipoprotein cholesterolBack to article page